Ab­b­Vie los­es a round in the heavy­weight biosim­i­lar fight over Hu­mi­ra patents

Few drugs at­tract the kind of at­ten­tion from the biosim­i­lars crowd that Hu­mi­ra war­rants. Ab­b­Vie gets the li­on’s share of its rev­enue from this $16 bil­lion be­he­moth and the bio­phar­ma com­pa­ny has sworn to guard its patents with a le­gion of the best paid at­tor­neys in the field.

But the gener­ics crowd con­tin­ues to chip away at its IP foun­da­tion.

On Tues­day Co­herus Bio­Science scored a key win in its on­go­ing bat­tle to mar­ket a knock­off. The US Patent and Trade­mark Of­fice’s Patent Tri­al and Ap­peals Board ruled in its fa­vor on one of a set of patents, for ‘135, trig­ger­ing an 8% surge in its share price $CHRS and a 2.3% drop for Ab­b­Vie $AB­BV.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.